ArticleOncogene2000
Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 79 citations in OpenAlex.
- lncRNAs as Biomarkers of Hepatocellular Carcinoma Risk and Liver Damage in Advanced Chronic Hepatitis C.Current issues in molecular biology · 2025Article
- Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets.Expert opinion on therapeutic targets · 2022Article
- Case-based review: atypical teratoid/rhabdoid tumor.Neuro-oncology practice · 2019Review
- The Aryl Hydrocarbon Receptor and Tumor Immunity.Frontiers in immunology · 2018Review
- The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Trends in cancer · 2017Review
- Identification of stanniocalcin 2 as a novel aryl hydrocarbon receptor target gene.The Journal of pharmacology and experimental therapeutics · 2013Article
- p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis.Oncogene · 2011Article
- SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells.Journal of cellular physiology · 2010Article
- The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis.Cancer research · 2010Article
- The developmentally-regulated Smoc2 gene is repressed by Aryl-hydrocarbon receptor (Ahr) signaling.Gene · 2009Article
- The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways.Biochemical pharmacology · 2009Review
- The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a.Molecular cancer · 2009Article
- The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis.Molecular biology of the cell · 2008Article
- Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.Cancer research · 2008Article
- Repression of Ah receptor and induction of transforming growth factor-beta genes in DEN-induced mouse liver tumors.Toxicology · 2008Article
- Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation.Oncogene · 2008Article
- RB activity alters checkpoint response and chemosensitivity in lung cancer lines.The Journal of surgical research · 2007Article
- The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle.Oncogene · 2005Article
- BRG1 controls the activity of the retinoblastoma protein via regulation of p21CIP1/WAF1/SDI.Molecular and cellular biology · 2004Article
- Hypoxia-induced irreversible S-phase arrest involves down-regulation of cyclin A.Cell proliferation · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Phosphorylation/inactivation of RB is typically required for cell cycle progression. However, we have identified a tumor cell line, C33A, which progresses through the cell cycle in the presence of an active allele of RB (PSM-RB). To determine how C33A cells evade RB-mediated arrest, we compared RB signaling to downstream effectors in this resistant cell line to that of the RB-sensitive SAOS-2 cell line. Although introduction of PSM-RB repressed E2F-mediated transcription in both C33A and SAOS-2 cells, PSM-RB failed to repress Cyclin A promoter activity in C33A. Ectopic expression of PSM-RB in SAOS-2 cells resulted in a decrease in both Cyclin A and Cdk2 protein levels without affecting Cyclin E or Cdk4. In contrast, over-expression of PSM-RB in C33A cells did not alter endogenous Cyclin A, Cyclin E, or Cdk2 protein levels or impact Cdk2 kinase activity, indicating that signaling from RB to down-stream targets is abrogated in this cell line. The importance of Cdk2 activity was demonstrated by p27Kip1, which attenuated Cdk2 activity and inhibited cell cycle progression in C33A cells. Since RB signaling to Cdk2 is disrupted in these tumor cells, we co-expressed two proteins that cooperate with RB in transcriptional repression, AHR and BRG-1, in an attempt to correct this signaling dysfunction. Co-expression of AHR/BRG-1 with PSM-RB attenuated Cyclin A and Cdk2 expression as well as Cdk2-associated kinase activity, resulting in cell cycle inhibition of C33A cells. Importantly, ectopic expression of Cyclin A was able to reverse the arrest mediated by co-expression of AHR/BRG-1 with PSM-RB. These results indicate that down-regulation of Cdk2 activity is requisite for RB-mediated cell cycle arrest. Thus, this study reveals a new mechanism through which tumor cells evade anti-proliferative signals, and provides insight into how RB-signaling is mediated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.